Immunology News and Research

Latest Immunology News and Research

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.

13 Jul 2010

Scientists receive $1.6M in new funding to advance healthcare research

University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.

13 Jul 2010

Two missing genes can develop aggressive form of leukaemia in mice: Research

A completely new mechanism that leads to the development of a certain type of leukaemia could eventually be targeted by new treatments, according to research published in Nature Immunology today (Sunday).

12 Jul 2010

Researchers demonstrate that MSNs can effectively suppress tumors in mice

The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.

12 Jul 2010

Merck details global restructuring program

Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.

9 Jul 2010

NIAID announces $14M in first-year funding to establish 10 new malaria research centers

In an effort to accelerate the control of malaria and help eliminate it worldwide, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced approximately $14 million in first-year funding to establish 10 new malaria research centers around the world.

9 Jul 2010

Conference bursary for researchers in developing countries to attend 'Parasite to Prevention'

Today, BioMed Central announced a fund to help researchers in developing countries attend the conference, Parasite to Prevention. The conference, held in conjunction with Malaria Journal, takes place in Edinburgh UK, 20-22 October 2010.

9 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Australian and Vietnamese researchers have estimated the current prevalence of Type 2 diabetes in Vietnam, and have developed a simple tool for identifying individuals at high risk.

9 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

IQPC presents Biopharmaceutical Nanotechnology Scientific Forum taking place August 16-18 in Philadelphia, PA.

From IQPC Ltd 8 Jul 2010

Vitamin D receptor emerges as key player amid gut bacteria, scientists find

Within the human digestive tract is a teeming mass of hundreds of types of bacteria, a potpourri of microbes numbering in the trillions that help us digest food and keep bad bacteria in check.

8 Jul 2010

MicroRNA-212 plays key role in determining vulnerability to cocaine addiction: Study

Scientists from The Scripps Research Institute have found that a particular type of genetic material plays a key role in determining vulnerability to cocaine addiction and may offer an entirely new direction for the development of anti-addiction therapies. In animal studies, the scientists found that a molecule called microRNA-212 was increased in the brains of test animals that had extended access to cocaine.

8 Jul 2010

Scientists identify new strategy for treating movement disorders

Scientists at the Gladstone Institute of Neurological Disease and Stanford University have shown how key circuits in the brain control movement. The research, published in the journal Nature not only establishes the function of these circuits, but offers promise for treating movement related disorders, such as Parkinson's disease.

8 Jul 2010

Insights into complex interrelationships between heart and kidneys

Research is yielding new understanding of the interactions between the heart and the kidneys—particularly the cardiorenal syndrome, in which failure of either organ can lead to failure of the other. Recent insights into the complex interrelationships between the heart and kidneys are presented in a special symposium section of the July issue of The American Journal of Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.

7 Jul 2010

Trigger that induces B cells to produce early, effective antibody response discovered

Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.

7 Jul 2010

Study identifies factors that control production of HSCs

A team of researchers from the Institute for Research in Immunology and Cancer of the University of Montreal have made significant progress in the understanding of blood-producing (hematopoietic) stem cells. The study led by IRIC Chief Executive Officer and Scientific Director, Dr. Guy Sauvageau, identifies factors that control the production of hematopoietic stem cells.

7 Jul 2010

Communication between bacterial species promotes resistance to antibiotics: Study

Ear infections caused by more than one species of bacteria could be more persistent and antibiotic-resistant because one pathogen may be communicating with the other, encouraging it to bolster its defenses. Interrupting or removing that communication could be key to curing these infections. Researchers from Wake Forest University Baptist Medical Center publish their findings today in mBio-, the online open-access journal of the American Society for Microbiology.

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

In their latest research, scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the growth of glioblastomas. Of all brain tumors, glioblastomas are among the most common and most aggressive.

7 Jul 2010

Immunology News and Research

Latest Immunology News and Research

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

Scientists receive $1.6M in new funding to advance healthcare research

Two missing genes can develop aggressive form of leukaemia in mice: Research

Researchers demonstrate that MSNs can effectively suppress tumors in mice

Merck details global restructuring program

NIAID announces $14M in first-year funding to establish 10 new malaria research centers

Conference bursary for researchers in developing countries to attend 'Parasite to Prevention'

IRIC scientists identify vitamin B3 as potential antifungal treatment

Australian, Vietnamese researchers develop simple tool for identifying individuals at high risk of Type 2 diabetes

Calithera Biosciences completes Series A financing totaling $40M

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

Vitamin D receptor emerges as key player amid gut bacteria, scientists find

MicroRNA-212 plays key role in determining vulnerability to cocaine addiction: Study

Scientists identify new strategy for treating movement disorders

Insights into complex interrelationships between heart and kidneys

Trigger that induces B cells to produce early, effective antibody response discovered

Study identifies factors that control production of HSCs

Communication between bacterial species promotes resistance to antibiotics: Study

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut